Literature DB >> 26980024

BRAF and epithelial-mesenchymal transition in primary cutaneous melanoma: a role for Snail and E-cadherin?

Brendon Mitchell1, Dominick A Leone2, John K Feller3, Shi Yang4, Meera Mahalingam5.   

Abstract

In vitro studies in melanoma indicate that up-regulation of the transcriptional repressor Snail occurs with a concomitant decrease of its target E-cadherin, both hallmarks of epithelial-mesenchymal transition-an association not established in vivo. We sought to elucidate the relationship between BRAF, Snail, E-cadherin, and established histopathologic prognosticators in primary cutaneous melanoma. Archived annotated samples with a diagnosis of primary cutaneous melanoma were retrieved (n = 68 cases; 34 BRAF mutant and 34 BRAF wild type) and immunohistochemically stained for Snail and E-cadherin protein expression. A semiquantitative scoring system was used. Multivariate logistic analysis was used to control confounders of BRAF. Snail expression was significantly associated only with ulceration (42% versus 13%; P = .02). E-cadherin expression was present in 26% of BRAF mutant and 71% of BRAF wild-type cases (P = .0003). Loss of E-cadherin expression was associated with female sex (60% versus 34%; P = .05), BRAF mutation (74% versus 29%; P = .0003), thickness greater than or equal to 1 mm (68% versus 32%; P = .004), mitosis (63% versus 25%; P = .007), and ulceration (75% versus 44%; P = .05). BRAF mutation was associated with male sex (60% versus 30%; P = .02), Breslow thickness (P = .007), thickness greater than or equal to 1 mm (68% versus 29%; P = .002), and ulceration (75% versus 42%; P = .02). Snail expression did not correlate with loss of E-cadherin expression (47% versus 53%; P = .79). After controlling for potential confounding, BRAF mutation was associated with loss of E-cadherin (adjusted odds ratio, 8.332; 95% confidence interval, 2.257-30.757; P = .0015) and Breslow thickness greater than 1 mm (adjusted odds ratio, 7.360; 95% confidence interval, 1.534-35.318; P = .0126). Our findings, indicating that mutant BRAF represses E-cadherin expression, implicating a catalytic role for BRAF in epithelial-mesenchymal transition. Published by Elsevier Inc.

Entities:  

Keywords:  BRAF; E-cadherin; Epithelial-mesenchymal transition; Primary cutaneous melanoma; Snail

Mesh:

Substances:

Year:  2016        PMID: 26980024     DOI: 10.1016/j.humpath.2015.12.030

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

1.  Epithelial-Mesenchymal Expression Phenotype of Primary Melanoma and Matched Metastases and Relationship with Overall Survival.

Authors:  Shaofeng Yan; Britt M Holderness; Zhongze Li; Gregory D Seidel; Jiang Gui; Jan L Fisher; Marc S Ernstoff
Journal:  Anticancer Res       Date:  2016-12       Impact factor: 2.480

2.  Therapeutic inhibition of microRNA-21 (miR-21) using locked-nucleic acid (LNA)-anti-miR and its effects on the biological behaviors of melanoma cancer cells in preclinical studies.

Authors:  Shaghayegh Haghjooy Javanmard; Golnaz Vaseghi; Ahmad Ghasemi; Laleh Rafiee; Gordon A Ferns; Hajar Naji Esfahani; Reza Nedaeinia
Journal:  Cancer Cell Int       Date:  2020-08-10       Impact factor: 5.722

3.  MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAFV600E-Driven Melanoma Growth In Vivo and BRAF/MEK Inhibitor Resistance.

Authors:  Bongyong Lee; Anupama Sahoo; Junko Sawada; John Marchica; Sanjay Sahoo; Fabiana I A L Layng; Darren Finlay; Joseph Mazar; Piyush Joshi; Masanobu Komatsu; Kristiina Vuori; Petrus R de Jong; Animesh Ray; Ranjan J Perera
Journal:  J Invest Dermatol       Date:  2020-09-02       Impact factor: 8.551

Review 4.  Ulcerated Cutaneous Melanoma: A Review of the Clinical, Histologic, and Molecular Features Associated with a Clinically Aggressive Histologic Phenotype.

Authors:  Zoe Barricklow; Mallory J DiVincenzo; Colin D Angell; William E Carson
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-30

Review 5.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.